• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

    3/25/25 4:03:00 AM ET
    $IH
    Other Consumer Services
    Real Estate
    Get the next $IH alert in real time by email

    BEIJING, March 25, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024.

    (PRNewsfoto/iHuman Inc.)

    Fourth Quarter 2024 Highlights

    • Revenues were RMB232.7 million (US$31.9 million), compared with RMB250.4 million in the same period last year.
    • Gross profit was RMB156.4 million (US$21.4 million), compared with RMB178.2 million in the same period last year.
    • Operating income was RMB14.9 million (US$2.0 million), compared with RMB21.9 million in the same period last year.
    • Net income was RMB26.5 million (US$3.6 million), compared with RMB33.3 million in the same period last year.
    • Average total MAUs[1] for the fourth quarter were 25.78 million, compared with 25.38 million in the same period last year.

    Fiscal Year 2024 Highlights

    • Revenues were RMB922.2 million (US$126.3 million), compared with RMB1,018.1 million in fiscal year 2023.
    • Gross profit was RMB640.2 million (US$87.7 million), compared with RMB721.3 million in fiscal year 2023.
    • Operating income was RMB71.9 million (US$9.9 million), compared with RMB159.9 million in fiscal year 2023.
    • Net income was RMB98.6 million (US$13.5 million), compared with RMB180.9 million in fiscal year 2023.
    • Average total MAUs were 26.47 million, compared with 23.04 million in the fiscal year 2023.

    [1] "Average total MAUs" refers to the monthly average of the sum of the MAUs of each of the Company's apps during a specific period, which is counted based on the number of unique mobile devices through which such app is accessed at least once in a given month, and duplicate access to different apps is not eliminated from the total MAUs calculation.

    Dr. Peng Dai, Director and Chief Executive Officer of iHuman, commented, "As we navigated evolving market conditions, we concluded 2024 with a robust and diversified product portfolio, further enhanced with more AI-integrated features that reinforces our leadership in the industry.

    At the heart of our success is our long-standing dedication to technological innovation, particularly in artificial intelligence. Since establishing our AI Lab in 2018, we have consistently invested in cutting-edge advancements and seamlessly integrated them into our product offerings. By embracing transformative technologies such as AI-generated content (AIGC), we became one of the first companies in China to develop and launch a proprietary large language model (LLM), a breakthrough that now powers a comprehensive range of our offerings and elevates our user experience to new heights. Take iHuman Smart Coder as an example. Leveraging our LLM, we have transformed a traditional coding course into a highly engaging, personalized learning experience that provides real-time tailored guidance and support. Children benefit from a personalized virtual coding mentor by their side that can analyze their code, pinpoint bugs, and provide corrective feedback through features such as intuitive voice prompts, graphics, and animations, making learning more fun and accessible. Additionally, we have introduced an innovative learning framework that combines challenge-based exploration, project-driven creativity, and immersive robotics sessions. Our robotics session features a 3D interactive blueprint that enables users to visualize each step of the build, making it possible to assemble intricate robots online. Our proprietary high-intelligence controller and custom code editor further enhance the experience, allowing children to program more sophisticated and intelligent robot behaviors. Together, these innovations create a coding experience that not only inspires and engages users, but also delivers tangible outcomes. Within months of its launch, some young users successfully passed the online exam administered by the Chinese Institute of Electronics, earning the Blocks Programming Level 1 Certificate.

    While pushing the boundaries of innovation from within, we also closely monitor emerging market trends, swiftly embracing new technological breakthroughs to enhance our products and maintain a competitive edge. Our early adoption of the revolutionary DeepSeek models—beginning with the V2 model in May 2024 and now fully integrating the latest R1 model across our core offerings—demonstrates our agility and forward-thinking approach. By seamlessly integrating our extensive in-house AI expertise with best-in-class third-party solutions, we deliver a more personalized, dynamic, and intelligent product experience that is tailored to each child's unique developmental needs and preferences.

    As we look ahead to 2025, I am confident that our forward-thinking approach—anchored in technological excellence and creative content—will keep us at the forefront of the industry and pave the way for another promising year of growth and innovation," concluded Dr. Dai.

    Ms. Vivien Weiwei Wang, Director and Chief Financial Officer of iHuman, added, "Despite facing some pressure from evolving market conditions, we are proud to report another quarter of profitability, marking our 12th consecutive quarter of positive earnings and our third consecutive year of profitability since our IPO in 2020. This consistent performance reflects the resilience of our business model and our ability to deliver sustainable growth. Meanwhile, our board of directors has approved a special cash dividend of US$0.02 per ordinary share, or US$0.10 per American Depositary Share (ADS) for the second consecutive year, which reflects our confidence in the financials and commitment to delivering shareholder value.

    During the quarter, our animation studio, Kunpeng, made significant strides in both commercialization and global expansion. Capitalizing on the breakout success of the Rainbow Crew animated series, unveiled in October 2024, we introduced themed merchandise, including magic wands and stickers, with additional products currently in development. These initiatives have further enhanced the brand's presence and deepened fan engagement across multiple touchpoints. Additionally, we launched an official Rainbow Crew channel on YouTube, sharing select clips from the series. These videos have received warm feedback and strong engagement, helping build awareness among international audiences, laying the foundation for the overseas expansion of the series.

    In addition to enriching our product portfolio, we have also effectively leveraged popular social media platforms to broaden our influence and expand our market reach. Our in-house IP, Two Cats (liamiao)—designed to spark interest in English and develop language awareness through engaging comics—has gained significant traction on Red Note, amassing over 240,000 followers and nearly 700,000 likes and saves in just a few months. This highlights our ability to engage audiences across diverse platforms and build meaningful connections with our users.

    As we continue to make solid progress with our business, we remain focused on driving product innovation through ongoing advancements in content and technology. We are committed to translating our strategic investments into lasting value for our shareholders, users, and the broader industry."

    Fourth Quarter 2024 Unaudited Financial Results

    Revenues

    Revenues were RMB232.7 million (US$31.9 million), a decrease of 7.1% from RMB250.4 million in the same period last year, primarily due to the decline in China's newborn population and more conservative consumer spending. 

    Average total MAUs for the quarter were 25.78 million, compared with 25.38 million in the same period last year.

    Cost of Revenues

    Cost of revenues was RMB76.2 million (US$10.4 million), compared with RMB72.2 million in the same period last year.

    Gross Profit and Gross Margin

    Gross profit was RMB156.4 million (US$21.4 million), a decrease of 12.2% from RMB178.2 million in the same period last year. Gross margin was 67.2%, compared with 71.2% in the same period last year. The decrease in gross margin was mainly due to the diversification and structural upgrades of the Company's product portfolio, especially with an increased focus on the offline component of its integrated online-offline strategy to boost the overall appeal of its offerings.

    Operating Expenses

    Total operating expenses were RMB141.5 million (US$19.4 million), a decrease of 9.5% from RMB156.4 million in the same period last year.

    Research and development expenses were RMB63.3 million (US$8.7 million), a decrease of 4.5% from RMB66.3 million in the same period last year. 

    Sales and marketing expenses were RMB54.1 million (US$7.4 million), a decrease of 16.1% from RMB64.5 million in the same period last year, primarily due to strategic savings in spending on marketing activities in the fourth quarter.

    General and administrative expenses were RMB24.1 million (US$3.3 million), a decrease of 5.6% from RMB25.5 million in the same period last year, primarily due to decreases in share-based compensation, as well as other administrative expenses. 

    Operating Income 

    Operating income was RMB14.9 million (US$2.0 million), compared with RMB21.9 million in the same period last year.

    Net Income 

    Net income was RMB26.5 million (US$3.6 million), compared with RMB33.3 million in the same period last year.

    Basic and diluted net income per ADS were RMB0.51 (US$0.07) and RMB0.49 (US$0.07), respectively, compared with RMB0.63 and RMB0.61 in the same period last year. Each ADS represents five Class A ordinary shares of the Company.

    Deferred Revenue and Customer Advances

    Deferred revenue and customer advances were RMB283.3 million (US$38.8 million) as of December 31, 2024, compared with RMB318.6 million as of December 31, 2023.

    Cash, Cash Equivalents and Short-term Investments

    Cash, cash equivalents and short-term investments were RMB1,168.7 million (US$160.1 million) as of December 31, 2024, compared with RMB1,213.8 million as of December 31, 2023.

    Fiscal Year 2024 Unaudited Financial Results

    Revenues

    Revenues were RMB922.2 million (US$126.3 million), a decrease of 9.4% from RMB1,018.1 million in fiscal year 2023, primarily due to the decline in China's newborn population and more conservative consumer spending.

    Average total MAUs were 26.47 million, an increase of 14.9% year-over-year from 23.04 million in fiscal year 2023, primarily due to the effective execution of our user acquisition strategy, particularly with the user expansion in overseas markets. 

    Cost of Revenues

    Cost of revenues was RMB282.0 million (US$38.6 million), a decrease of 5.0% year-over-year from RMB296.9 million in fiscal year 2023, primarily due to decreased channel costs.

    Gross Profit and Gross Margin

    Gross profit was RMB640.2 million (US$87.7 million), a decrease of 11.2% from RMB721.3 million in fiscal year 2023. Gross margin was 69.4%, compared with 70.8% in fiscal year 2023. The decrease in gross margin was mainly due to the diversification and structural upgrades of the Company's product portfolio, especially with an increased focus on the offline component of its integrated online-offline strategy to boost the overall appeal of its offerings.

    Operating Expenses

    Total operating expenses were RMB568.2 million (US$77.8 million), compared with RMB561.4 million in fiscal year 2023.

    Research and development expenses were RMB247.8 million (US$33.9 million), a decrease of 3.8% from RMB257.5 million in fiscal year 2023.

    Sales and marketing expenses were RMB221.2 million (US$30.3 million), an increase of 10.9% from RMB199.5 million in fiscal year 2023, primarily due to increased strategic spending on promotional activities, brand enhancement, and overseas expansion.

    General and administrative expenses were RMB99.3 million (US$13.6 million), a decrease of 4.9% from RMB104.3 million in fiscal year 2023.

    Operating Income

    Operating income was RMB71.9 million (US$9.9 million), compared with RMB159.9 million in fiscal year 2023.

    Net Income

    Net income was RMB98.6 million (US$13.5 million), compared with RMB180.9 million in fiscal year 2023.

    Basic and diluted net income per ADS were RMB1.88 (US$0.26) and RMB1.82 (US$0.25), respectively, compared with RMB3.43 and RMB3.30 in fiscal year 2023. Each ADS represents five Class A ordinary shares of the Company.

    Special Cash Dividend

    To deliver return of capital to shareholders, the Company's board of directors (the "Board") approved a special cash dividend of US$0.02 per ordinary share, or US$0.10 per ADS, to holders of ordinary shares and holders of ADSs as of the close of business on April 17, 2025 New York Time, payable in U.S. dollars. The aggregate amount of the special dividend will be approximately US$5.2 million. The payment date is expected to be on or around May 8, 2025 and May 15, 2025 for holders of ordinary shares and holders of ADSs, respectively.

    Exchange Rate Information

    The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the reader. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of December 31, 2024, which was RMB7.2993 to US$1.00. The percentages stated in this press release are calculated based on the RMB amounts.

    Non-GAAP Financial Measures

    iHuman considers and uses non-GAAP financial measures, such as adjusted operating income, adjusted net income and adjusted diluted net income per ADS, as supplemental metrics in reviewing and assessing its operating performance and formulating its business plan. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). iHuman defines adjusted operating income, adjusted net income and adjusted diluted net income per ADS as operating income, net income and diluted net income per ADS excluding share-based compensation expenses, respectively. Adjusted operating income, adjusted net income and adjusted diluted net income per ADS enable iHuman's management to assess its operating results without considering the impact of share-based compensation expenses, which are non-cash charges. iHuman believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating the Company's current operating performance and prospects in the same manner as management does, if they so choose.

    Non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-GAAP financial measures. In addition, the non-GAAP financial measures iHuman uses may differ from the non-GAAP measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about iHuman's beliefs and expectations, are forward-looking statements. Among other things, the description of the management's quotations in this announcement contains forward-looking statements. iHuman may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iHuman's growth strategies; its future business development, financial condition and results of operations; its ability to continue to attract and retain users, convert non-paying users into paying users and increase the spending of paying users, the trends in, and size of, the market in which iHuman operates; its expectations regarding demand for, and market acceptance of, its products and services; its expectations regarding its relationships with business partners; general economic and business conditions; regulatory environment; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in iHuman's filings with the SEC. All information provided in this press release is as of the date of this press release, and iHuman does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    About iHuman Inc.

    iHuman Inc. is a leading provider of tech-powered, intellectual development products in China that is committed to making the child-upbringing experience easier for parents and transforming intellectual development into a fun journey for children. Benefiting from a deep legacy that combines over two decades of experience in the parenthood industry, superior original content, advanced high-tech innovation DNA and research & development capabilities with cutting-edge technologies, iHuman empowers parents with tools to make the child-upbringing experience more efficient. iHuman's unique, fun and interactive product offerings stimulate children's natural curiosity and exploration. The Company's comprehensive suite of innovative and high-quality products include self-directed apps, interactive content and smart devices that cover a broad variety of areas to develop children's abilities in speaking, critical thinking, independent reading and creativity, and foster their natural interest in traditional Chinese culture. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children's behavior & psychology, iHuman believes it will continue to provide superior experience that is efficient and relieving for parents, and effective and fun for children, in China and all over the world, through its integrated suite of tech-powered, intellectual development products.

    For more information about iHuman, please visit https://ir.ihuman.com/.

    For investor and media enquiries, please contact:

    iHuman Inc.

    Mr. Justin Zhang

    Investor Relations Director

    Phone: +86-10-5780-6606

    E-mail: [email protected]

    Christensen

    In China

    Ms. Alice Li

    Phone: +86-10-5900-1548

    E-mail: [email protected] 

    In the US

    Ms. Linda Bergkamp

    Phone: +1-480-614-3004

    E-mail: [email protected]

    iHuman Inc.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares, ADSs, per share and per ADS data)





    December 31,



    December 31,



    December 31,



    2023



    2024



    2024



    RMB



    RMB



    US$













    ASSETS











    Current assets











    Cash and cash equivalents 

    1,213,767



    1,123,292



    153,890

    Short-term investments

    -



    45,457



    6,228

    Accounts receivable, net

    60,832



    52,030



    7,128

    Inventories, net

    16,518



    23,475



    3,216

    Amounts due from related parties

    1,810



    2,051



    281

    Prepayments and other current assets

    89,511



    89,512



    12,263

    Total current assets

    1,382,438



    1,335,817



    183,006

    Non-current assets











    Property and equipment, net

    6,169



    3,476



    476

    Intangible assets, net

    23,245



    16,429



    2,251

    Operating lease right-of-use assets

    3,648



    14,885



    2,039

    Long-term investment

    26,333



    26,333



    3,608

    Other non-current assets

    8,662



    22,701



    3,110

    Total non-current assets

    68,057



    83,824



    11,484

    Total assets

    1,450,495



    1,419,641



    194,490













    LIABILITIES











    Current liabilities











    Accounts payable

    22,139



    30,233



    4,142

    Deferred revenue and customer advances

    318,587



    283,251



    38,805

    Amounts due to related parties

    4,428



    1,734



    238

    Accrued expenses and other current liabilities

    143,677



    126,501



    17,331

    Dividend payable

    -



    2,164



    296

    Current operating lease liabilities

    1,927



    3,661



    502

    Total current liabilities

    490,758



    447,544



    61,314

    Non-current liabilities











    Non-current operating lease liabilities

    1,933



    11,252



    1,542

    Total non-current liabilities

    1,933



    11,252



    1,542

    Total liabilities

    492,691



    458,796



    62,856

    SHAREHOLDERS' EQUITY











    Ordinary shares (par value of US$0.0001 per share,

       700,000,000 Class A shares authorized as of

       December 31, 2023 and December 31, 2024;

       125,122,382 Class A shares issued and 119,704,787

       outstanding as of December 31, 2023; 125,122,382

       Class A shares issued and 116,084,207 outstanding as

       of December 31, 2024; 200,000,000 Class B shares

       authorized, 144,000,000 Class B ordinary shares

       issued and outstanding as of December 31, 2023 and   

       December 31, 2024; 100,000,000 shares

       (undesignated) authorized, nil shares (undesignated)

       issued and outstanding as of December 31, 2023 and   

       December 31, 2024)

    185



    185



    25

    Additional paid-in capital

    1,088,628



    996,657



    136,541

    Treasury stock

    (16,665)



    (26,296)



    (3,603)

    Statutory reserves

    8,164



    8,395



    1,150

    Accumulated other comprehensive income

    17,955



    24,009



    3,289

    Accumulated deficit

    (140,463)



    (42,105)



    (5,768)

    Total shareholders' equity

    957,804



    960,845



    131,634

    Total liabilities and shareholders' equity

    1,450,495



    1,419,641



    194,490

     

     

    iHuman Inc.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares, ADSs, per share and per ADS data)





    For the three months ended



    For the year ended



    December 31,



    September 30,



    December 31,



    December 31,



    December 31,



    December 31,



    December 31,



    2023



    2024



    2024



    2024



    2023



    2024



    2024



    RMB



    RMB



    RMB



    US$



    RMB



    RMB



    US$





























    Revenues

    250,447



    239,407



    232,684



    31,878



    1,018,139



    922,201



    126,341

    Cost of revenues

    (72,201)



    (75,541)



    (76,243)



    (10,445)



    (296,868)



    (282,048)



    (38,640)





























    Gross profit

    178,246



    163,866



    156,441



    21,433



    721,271



    640,153



    87,701





























    Operating expenses



























    Research and development expenses

    (66,293)



    (59,307)



    (63,308)



    (8,673)



    (257,546)



    (247,757)



    (33,943)

    Sales and marketing expenses

    (64,511)



    (60,863)



    (54,109)



    (7,413)



    (199,504)



    (221,230)



    (30,308)

    General and administrative expenses

    (25,547)



    (22,998)



    (24,106)



    (3,303)



    (104,334)



    (99,254)



    (13,598)

    Total operating expenses

    (156,351)



    (143,168)



    (141,523)



    (19,389)



    (561,384)



    (568,241)



    (77,849)

    Operating income

    21,895



    20,698



    14,918



    2,044



    159,887



    71,912



    9,852

    Other income, net

    8,965



    8,024



    12,245



    1,678



    42,686



    38,689



    5,300

    Income before income taxes

    30,860



    28,722



    27,163



    3,722



    202,573



    110,601



    15,152

    Income tax benefits (expenses)

    2,411



    (3,579)



    (682)



    (93)



    (21,666)



    (12,012)



    (1,646)

    Net income

    33,271



    25,143



    26,481



    3,629



    180,907



    98,589



    13,506





























    Net income per ADS:



























       - Basic

    0.63



    0.48



    0.51



    0.07



    3.43



    1.88



    0.26

       - Diluted

    0.61



    0.47



    0.49



    0.07



    3.30



    1.82



    0.25





























    Weighted average number of ADSs:



























       - Basic

    52,740,067



    52,283,334



    52,097,127



    52,097,127



    52,810,587



    52,400,383



    52,400,383

       - Diluted

    54,753,503



    54,011,420



    53,965,183



    53,965,183



    54,753,025



    54,239,751



    54,239,751





























    Total share-based compensation expenses included in:



























    Cost of revenues

    64



    22



    18



    2



    299



    106



    15

    Research and development expenses

    1,115



    225



    273



    37



    4,055



    1,303



    179

    Sales and marketing expenses

    122



    39



    34



    5



    707



    164



    22

    General and administrative expenses

    817



    329



    229



    31



    4,374



    1,251



    171





























     

     

    iHuman Inc.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

    except for number of shares, ADSs, per share and per ADS data)







    For the three months ended



    For the year ended



    December 31,



    September 30,



    December 31,



    December 31,



    December 31,



    December 31,



    December 31,



    2023



    2024



    2024



    2024



    2023



    2024



    2024



    RMB



    RMB



    RMB



    US$



    RMB



    RMB



    US$





























    Operating income

    21,895



    20,698



    14,918



    2,044



    159,887



    71,912



    9,852

    Share-based compensation expenses

    2,118



    615



    554



    75



    9,435



    2,824



    387

    Adjusted operating income

    24,013



    21,313



    15,472



    2,119



    169,322



    74,736



    10,239





























    Net income

    33,271



    25,143



    26,481



    3,629



    180,907



    98,589



    13,506

    Share-based compensation expenses

    2,118



    615



    554



    75



    9,435



    2,824



    387

    Adjusted net income

    35,389



    25,758



    27,035



    3,704



    190,342



    101,413



    13,893





























    Diluted net income per ADS

    0.61



    0.47



    0.49



    0.07



    3.30



    1.82



    0.25

    Impact of non-GAAP adjustments

    0.04



    0.01



    0.01



    0.00



    0.18



    0.05



    0.01

    Adjusted diluted net income per ADS

    0.65



    0.48



    0.50



    0.07



    3.48



    1.87



    0.26





























    Weighted average number of ADSs – diluted

    54,753,503



    54,011,420



    53,965,183



    53,965,183



    54,753,025



    54,239,751



    54,239,751

    Weighted average number of ADSs – adjusted

    54,753,503



    54,011,420



    53,965,183



    53,965,183



    54,753,025



    54,239,751



    54,239,751

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ihuman-inc-announces-fourth-quarter-and-fiscal-year-2024-unaudited-financial-results-302410361.html

    SOURCE iHuman Inc.

    Get the next $IH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IH

    DatePrice TargetRatingAnalyst
    12/30/2022$3.10Buy
    Citigroup
    More analyst ratings

    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by iHuman Inc. (Amendment)

      SC 13G/A - iHuman Inc. (0001814423) (Subject)

      3/8/22 10:06:04 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • SEC Form SC 13G/A filed by iHuman Inc. (Amendment)

      SC 13G/A - iHuman Inc. (0001814423) (Subject)

      2/14/22 4:13:25 PM ET
      $IH
      Other Consumer Services
      Real Estate
    • SEC Form SC 13G filed

      SC 13G - iHuman Inc. (0001814423) (Subject)

      2/16/21 6:11:44 AM ET
      $IH
      Other Consumer Services
      Real Estate

    $IH
    Financials

    Live finance-specific insights

    See more

    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IH
    SEC Filings

    See more
    • iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

      BEIJING, March 25, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Highlights Revenues were RMB232.7 million (US$31.9 million), compared with RMB250.4 million in the same period last year.Gross profit was RMB156.4 million (US$21.4 million), compared with RMB178.2 million in the same period last year.Operating income was RMB14.9 million (US$2.0 m

      3/25/25 4:03:00 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • iHuman Inc. Announces Third Quarter 2024 Unaudited Financial Results

      BEIJING, Dec. 26, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2024.   Third Quarter 2024 Highlights Revenues were RMB239.4 million (US$34.1 million), compared with RMB261.5 million in the same period last year.Gross profit was RMB163.9 million (US$23.4 million), compared with RMB186.6 million in the same period last year.Operating income was RMB20.7 million (US$2.9 million), compare

      12/26/24 3:18:00 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • iHuman Inc. Announces Second Quarter 2024 Unaudited Financial Results

      BEIJING, Sept. 27, 2024 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Revenues were RMB215.1 million (US$29.6 million), compared with RMB241.0 million in the same period last year.Gross profit was RMB151.7 million (US$20.9 million), compared with RMB170.8 million in the same period last year.Operating income was RMB18.8 million (US$2.6 million), compared wi

      9/27/24 5:47:00 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 10:44:07 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 8:35:00 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • iHuman Inc. Files 2024 Annual Report on Form 20-F

      BEIJING, April 28, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 28, 2025. The annual report on Form 20-F is available on the Company's investor relations website at https://ir.ihuman.com/. iHuman will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements for the year ended December 31, 2024, free of charge, to its shareholders and ADS holders upon request. Requests should be directed t

      4/28/25 4:40:00 PM ET
      $IH
      Other Consumer Services
      Real Estate
    • SEC Form 20-F filed by iHuman Inc.

      20-F - iHuman Inc. (0001814423) (Filer)

      4/28/25 4:01:23 PM ET
      $IH
      Other Consumer Services
      Real Estate
    • SEC Form 6-K filed by iHuman Inc.

      6-K - iHuman Inc. (0001814423) (Filer)

      3/25/25 7:10:38 AM ET
      $IH
      Other Consumer Services
      Real Estate
    • SEC Form 6-K filed by iHuman Inc.

      6-K - iHuman Inc. (0001814423) (Filer)

      12/26/24 6:01:05 AM ET
      $IH
      Other Consumer Services
      Real Estate

    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on iHuman with a new price target

      Citigroup resumed coverage of iHuman with a rating of Buy and set a new price target of $3.10

      12/30/22 8:45:58 AM ET
      $IH
      Other Consumer Services
      Real Estate